Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) still undergoing phase III trials, whilst sermorelin is an unlicensed growth hormone-releasing hormone analogue
However, in view of the estimated 1% of total absorption via passive diffusion in patients with pernicious anemia, a 1000 g daily dose is recommended
27 July 2010" (PDF)
Xu Y, Sang W, Zhong Y, Xue S, Yang M, Wang C, et al
It is not the first time a potential link has been mooted patient leaflets for Mounjaro and Wegovy list it as a common side-effect
This hormone plays a crucial role in blood sugar regulation by stimulating insulin release and lowering glucagon levels, helping the body maintain stable glucose control